Clinical Trial Update: Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and safety study of a single dose of PF-06480605 in Chinese healthy participants completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• PF-06480605

Snippet

Sponsor: Pfizer | Conditions: Inflammatory Bowel Disease | Phase 1 | Status: COMPLETED | Results posted: 2024-03-21